Heron Therapeutics Sustains Q1 Growth, Advances Late-Stage Pain Pipeline
Heron Therapeutics sustained year-over-year revenue gains in Q1 2026 despite increased R&D spending tied to its analgesic portfolio expansion. Management confirmed full-year guidance and highlighted initiation of pivotal trials for its late-stage pain management candidates.
1. Earnings Call Highlights
Heron Therapeutics reported resilient Q1 2026 financials, achieving year-over-year revenue gains while absorbing higher research and development costs associated with its expanding analgesic product portfolio. Management reiterated its fiscal 2026 outlook and detailed progress across its late-stage pipeline, including the launch of pivotal trials for novel pain management therapies.
Related News
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
GILD
Gilead Launches Five-Year WHO Collaboration with $9.2M Aid and 400,000 AmBisome Vials
GILD•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
TOL
Toll Brothers Beats Q2 Revenue Guidance by $110M, Raises Delivery and Buyback Plans
TOL•
Sources
F